Condition: Chronic Spontaneous Urticaria · Chronic Urticaria, Idiopathic · Sponsor: Simon Francis Thomsen
This study is a multicentre, randomized, open-label, non-inferiority clinical trial. The purpose and aim of this study is to investigate if patients with well controlled (UCT score score ≥ 12) chronic spontaneous urticaria (CSU) on omalizumab 300 mg every four weeks can extend treatment intervals and maintain disease control.
This description comes directly from the study's public registry record.
Simon F Thomsen, MD, DMSc · +4526139838 · simon.francis.thomsen.02@regionh.dk
Ditte G Zhang, MD · +4520994864 · DZHA0006@regionh.dk
Always discuss trial participation with your own doctor first.
| Department of Dermatology, Bispebjerg Hospital | Copenhagen, Copenhagen N, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05916937